Ratings CompuGroup Medical Societas Europaea Xetra

Equities

COP

DE0005437305

Delayed Xetra Other stock markets 11:19:08 2021-10-05 EDT			5-day change	1st Jan Change
69.35 ^EUR	+1.31%		-7.31%	-12.91%

04-26	COMPUGROUP MEDICAL : Buy rating from Baader Bank	ZD
04-25	COMPUGROUP MEDICAL : Jefferies gives a Neutral rating	ZD

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

The company is in debt and has limited leeway for investment
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Software

	1st Jan change	Capi.	ESG Refinitiv
COMPUGROUP MEDICAL SOCIETAS EUROPAEA	-12.91%	1.59B	-
ORACLE CORPORATION	+11.17%	322B	B-
SAP SE	+24.75%	216B	B+
SERVICENOW, INC.	+2.41%	149B	B
CONSTELLATION SOFTWARE INC.	+10.65%	56.27B	D+
HUBSPOT, INC.	+8.71%	32.13B	B+
FAIR ISAAC CORPORATION	-4.57%	27.45B	C+
MICROSTRATEGY INCORPORATED	+103.03%	22.62B	D+
WISETECH GLOBAL LIMITED	+20.22%	19.55B	B-
SAGE GROUP PLC	+0.04%	14.61B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes